

**DECLARATION**  
**AND**  
**POWER OF ATTORNEY**

As a below named inventors, we hereby declare that:

Our residences, post office addresses and citizenships are as stated below next to our names.

We believe we are the original, first and joint inventors of the subject matter which is claimed and for which a patent is sought on the invention entitled ENZYME THERAPY FOR ATHEROSCLEROSIS, the specification of which

(check one) ☒ is attached hereto.

We hereby state that we have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

We acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

We hereby claim foreign priority benefits under Title 35, United States Code, §119(a)-(d) of any foreign application(s) for patent or inventor's certificate or of any PCT international applications designating at least one country other than the United States of America listed below and have also identified below any foreign application(s) for patent or inventor's certificate or any PCT international applications(s) designating at least one country other than the United States of America filed by us on the same subject matter having a filing date before that of the application(s) of which priority is claimed.

PRIOR FOREIGN APPLICATION(S) UNDER 35 U.S.C. 119(a)-(d)				
Number	Country	Filing Date	Priority Claimed	
			Yes	No

We hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below:

CLAIM FOR BENEFIT OF PRIOR U.S. PROVISIONAL APPLICATION(S) UNDER 35 U.S.C. 119(e)	
Provisional Application Number	Filing Date
60/180,362	February 4, 2001

We hereby claim the benefit under Title 35, United States Codes, §120, of any United States application(s) or PCT international application(s) designating the United States of America that is/are listed below and, insofar as the subject matter of each of the claims of this

"Express Mail" mailing label number  
E2 58388 617305  
2/2/01  
Date of Deposit  
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office Addressee" service under 39 CFR 1.15, the date indicated above and is being sent to Assistant Commissioner for Trademark, 2900 Crystal Drive, Arlington, Virginia 22202-3513.  
Kellie Akon  
(Typed or printed name of person mailing paper or fee)  
Signature



application is not disclosed in that/those prior application(s) in the manner provided by the first paragraph of Title 35, United States Code, §112, we acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56 that occurred between the filing date of the prior application(s) and the national or PCT international filing date of this application:

<b>PRIOR U.S. APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE U.S. FOR BENEFIT UNDER 35 U.S.C. 120</b>				
<b>U.S. Applications</b>		<b>Status (check one)</b>		
<b>U.S. Applications</b>	<b>Filing Date</b>	<b>Patented</b>	<b>Pending</b>	<b>Abandoned</b>


  

<b>PCT APPLICATIONS DESIGNATING THE U.S.</b>		
<b>Application No.</b>	<b>Filing Date</b>	<b>U.S. Application No. Assigned (if any)</b>

We hereby appoint Karlyn A. Schnapp, Registration No. 45,558; Edwin R. Acheson, Jr., Registration No. 31,808; Stephen R. Albainy-Jenei, Registration No. 41,487; Glenn D. Bellamy, Registration No. 32,887; William E. Gallagher, Registration No. 35,145; Steven J. Goldstein, Registration No. 28,079; Ann G. Robinson, Registration No. 39,820; Ria Farrell Schalnatt, Registration No. 47,058; David E. Schmit, Registration No. 28,472; Ralph J. Skinkiss, Registration No. 26,105; and Kevin S. Sprecher, Registration No. 42,165; c/o Frost Brown Todd LLC, 2200 PNC Center, 201 East Fifth Street, Cincinnati, Ohio 45202 (513) 651-6800 my attorneys, with full power in each of them, of substitution and revocation, to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith.

We hereby declare that all statements made herein of our own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Dr. Gregory Grabowski

Inventor's Signature  1/30/01  
(Date)

Residence: 1121 Rookwood Drive  
Citizenship: USA  
Post Office Address: Cincinnati, Ohio

Full name of second joint inventor: Dr. Hong Du

Inventor's Signature 16-2-2001 1-30-01  
(Date)

Residence: 1290 Winstone Court  
Citizenship: USA  
Post Office Address: Cincinnati, Ohio

CINlibrary/1016829.1


UNITED STATES PATENT AND TRADEMARK OFFICE  
DOCUMENT CLASSIFICATION BARCODE SHEET



**Miscellaneous**

**10**

United States Patent & Trademark Office  
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☐ Page(s) \_\_\_\_\_ of \_\_\_\_\_ were not present  
for scanning. (Document title)

☒ *Scanned copy is best available. Drawing.*

e. **Summary**

[0078] Limited treatment of *lal*<sup>-/-</sup> mice with LAL (10 injections in 30 days, 1.48 U/dose) led to gross, histologic and biochemical corrections of cholesterol and triglyceride levels in treated mice.

**2. Plasma chemistries and lipid levels in *lal*<sup>-/-</sup> and *ldlr*<sup>-/-</sup> mice.**

[0079] No differences in plasma glucose levels were observed in treated or untreated *lal*<sup>-/-</sup> or *ldlr*<sup>-/-</sup> mice although *ldlr*<sup>-/-</sup> mice have higher plasma glucose levels than wild type or *lal*<sup>-/-</sup> mice. The *lal*<sup>-/-</sup> and *ldlr*<sup>-/-</sup> mice had increased plasma non-esterified fatty acids (NEFA) levels compared to the wild-type controls (162% and 227%, respectively). LAL administration was associated with increases of the NEFA by 32.6% in *lal*<sup>-/-</sup> mice and 24.5% in *ldlr*<sup>-/-</sup> mice. Plasma triglycerides levels decreased in treated *lal*<sup>-/-</sup> mice, but were unchanged in *ldlr*<sup>-/-</sup> mice. The HFCD produced hypercholesterolemia in *ldlr*<sup>-/-</sup> mice. The plasma free cholesterol concentration increased 22-fold and plasma cholesteryl ester concentration increased 13.8-fold compared to wild-type mice. The LAL treated *ldlr*<sup>-/-</sup> mice had decreases in plasma free cholesterol of 18.2% (p=0.0894) and in cholesteryl esters of 26.7% (P=0.0025). The free cholesterol and cholesterol ester levels were unchanged in treated *lal*<sup>-/-</sup> mice.